Black Dog Institute, Sydney, New South Wales, Australia.
Curr Opin Psychiatry. 2013 Jan;26(1):33-40. doi: 10.1097/YCO.0b013e32835ab4a7.
To overview the theoretical relevance of omega-3 and omega-6 fatty acids in the cause of mood disorders, and focus on evaluating the potential therapeutic role of omega-3 fatty acids.
Numerous studies have documented low omega-3 fatty acid levels in those with depressive disorders, and there are plausible biological explanations as to why reduced omega-3 status may predispose to mood disorders as well as to a range of other conditions. Although early studies evaluating the role of omega-3 preparations as treatments of depression were generally positive, the rate of negative or nondifferential studies has increased in recent years. Recent meta-analyses provide an explanation in suggesting that docosahexaenoic acid-weighted preparations may be ineffective while finding support for eicosapentaenoic acid (EPA)-weighted preparations.
There is sufficient indicative data favouring EPA-weighted omega-3 supplementation for those with a depressive mood disorder, particular when fish oil is viewed by patients as 'natural,' it has few side effects and is neuroprotective. Recent meta-analyses inform us that intervention studies should focus on EPA-weighted preparations.
概述 ω-3 和 ω-6 脂肪酸在情绪障碍发病机制中的理论相关性,并重点评估 ω-3 脂肪酸的潜在治疗作用。
大量研究记录了抑郁症患者 ω-3 脂肪酸水平较低,并且有合理的生物学解释为什么 ω-3 状态降低可能导致情绪障碍以及一系列其他疾病。尽管早期评估 ω-3 制剂作为抑郁症治疗作用的研究总体上是积极的,但近年来阴性或无差异研究的比例有所增加。最近的荟萃分析提供了一个解释,表明二十二碳六烯酸加权制剂可能无效,而二十碳五烯酸(EPA)加权制剂则得到支持。
有足够的证据支持对有抑郁情绪障碍的患者进行 EPA 加权 ω-3 补充,特别是当鱼油被患者视为“天然”时,它的副作用很少,并且具有神经保护作用。最近的荟萃分析告诉我们,干预研究应集中在 EPA 加权制剂上。